111, Inc. Sponsored ADR (NASDAQ:YI – Get Free Report) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totaling 4,313 shares, a decline of 38.5% from the September 30th total of 7,014 shares. Based on an average trading volume of 12,201 shares, the short-interest ratio is currently 0.4 days. Approximately 0.1% of the company’s stock are short sold.
Analyst Ratings Changes
Separately, Weiss Ratings cut shares of 111 from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, October 13th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.
Check Out Our Latest Stock Analysis on 111
111 Price Performance
Shares of 111 stock opened at $2.90 on Friday. The stock has a market cap of $25.53 million, a price-to-earnings ratio of -1.82 and a beta of 0.67. The firm’s 50-day moving average is $3.33 and its 200 day moving average is $5.05. 111 has a 1 year low of $2.48 and a 1 year high of $11.17.
111 (NASDAQ:YI – Get Free Report) last announced its quarterly earnings data on Friday, September 18th. The company reported ($0.60) EPS for the quarter. The company had revenue of $338.55 million for the quarter.
111 Company Profile
111, Inc is a China-based healthcare technology company that operates an online platform connecting consumers, pharmaceutical manufacturers, distributors and healthcare providers. The company focuses on improving access to medicines and health-related products through digital retail and supply-chain services.
Its business includes online sales of prescription and over-the-counter medicines, nutritional products, medical devices and other healthcare products. Through its technology platform, 111 also provides services intended to support pharmaceutical companies and pharmacies with product distribution, marketing, data and fulfillment.
Founded in 2010 and headquartered in Shanghai, 111 serves customers and healthcare businesses in China.
Further Reading
- Five stocks we like better than 111
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for 111 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 111 and related companies with MarketBeat.com's FREE daily email newsletter.
